Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model.

摘要: Abstract Currently numerous clinical trials are in progress utilizing intracarotid (i.c.) 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of malignant gliomas based upon proposed focal nature these tumors and assumption that i.c. route delivers higher levels drug to tumor. To date, however, increased efficacy an animal model has not been clearly demonstrated delivery BCNU. We have evaluated dose-response curve i.v. administration BCNU a commonly utilized experimental brain tumor model, 9L rat gliosarcoma. An initial toxicity trial i.p. 10% lethal dose (LD 10 ) by routes failed demonstrate any significance between two routes. Tumor-bearing animals were then treated on Day 15–16 after inoculations with 1, 10, 25, 50, 75, 100% LD either or route. Both gave maximum survival increases at 75–100% doses, there was no therapeutic advantage seen from delivery. However, 50% (6.65 mg/kg), triplicate experiments but maintained equivalent given When reduced 25% (3.33 three showed this lower dosage be The resulted significant reduction all trials. At (1.30 neither nor retained . one trials, groups had statistically better than controls, while experiment over controls groups. 1% dose, efficacy. From our data, intracranial gliosarcoma appears fact significantly dosages those may achieve potentially less systemic toxicity.